COVID-19 大流行期间成人免疫性血小板减少症管理的实用指南。
Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic.
机构信息
Department of Haematology, Oxford University Hospitals, Oxford, UK.
Department of Haematology, Manchester University Foundation Trust, Manchester, UK.
出版信息
Br J Haematol. 2020 Jun;189(6):1038-1043. doi: 10.1111/bjh.16775. Epub 2020 Jun 2.
Abstract
This document aims to provide practical guidance for the assessment and management of patients with thrombocytopenia, with a particular focus on immune thrombocytopenia (ITP), during the COVID-19 pandemic. The intention is to support clinicians and, although recommendations have been provided, it is not a formal guideline. Nor is there sufficient evidence base to conclude that alternative approaches to treatment are incorrect. Instead, it is a consensus written by clinicians with an interest in ITP or coagulation disorders and reviewed by members of the UK ITP forum.
摘要
本文件旨在为 COVID-19 大流行期间血小板减少症患者的评估和管理提供实用指南，重点关注免疫性血小板减少症（ITP）。目的是为临床医生提供支持，虽然提出了建议，但这不是正式的指南。也没有足够的证据基础来得出替代治疗方法不正确的结论。相反，这是由对 ITP 或凝血障碍有兴趣的临床医生撰写并由英国 ITP 论坛成员审查的共识。
相似文献
1
Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic.COVID-19 大流行期间成人免疫性血小板减少症管理的实用指南。
Br J Haematol. 2020 Jun;189(6):1038-1043. doi: 10.1111/bjh.16775. Epub 2020 Jun 2.
2
SARS-CoV-2 infection in two pediatric patients with immune cytopenias: A single institution experience during the pandemic.两名患有免疫性血细胞减少症的儿科患者感染严重急性呼吸综合征冠状病毒2：大流行期间一家机构的经验
Pediatr Blood Cancer. 2020 Sep;67(9):e28503. doi: 10.1002/pbc.28503. Epub 2020 Jun 21.
3
Immune Thrombocytopenia (ITP) in a Pediatric Patient Positive for SARS-CoV-2.儿童 SARS-CoV-2 阳性患者的免疫性血小板减少症（ITP）。
Pediatrics. 2020 Aug;146(2). doi: 10.1542/peds.2020-1419. Epub 2020 May 21.
4
Guidance for the management of adult patients with coronavirus disease 2019.2019年冠状病毒病成人患者管理指南。
Chin Med J (Engl). 2020 Jul 5;133(13):1575-1594. doi: 10.1097/CM9.0000000000000899.
5
COVID-19-associated immune thrombocytopenia.新型冠状病毒肺炎相关免疫性血小板减少症
Br J Haematol. 2020 Jul;190(2):e61-e64. doi: 10.1111/bjh.16850. Epub 2020 Jun 8.
6
Coronavirus infection in cancer patients, last update.癌症患者中的冠状病毒感染，最新更新。
Med Clin (Barc). 2020 Oct 9;155(7):299-301. doi: 10.1016/j.medcli.2020.05.028. Epub 2020 Jul 15.
7
Practical Guidance for Outpatient Spasticity Management During the Coronavirus (COVID-19) Pandemic: Canadian Spasticity COVID-19 Task Force.冠状病毒（COVID-19）大流行期间门诊痉挛管理实用指南：加拿大痉挛COVID-19特别工作组
Can J Neurol Sci. 2020 Sep;47(5):589-593. doi: 10.1017/cjn.2020.104. Epub 2020 May 26.
8
Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists.重症新型冠状病毒2型感染：重症监护医生的实际考量与管理策略
Intensive Care Med. 2020 Apr;46(4):579-582. doi: 10.1007/s00134-020-05967-x. Epub 2020 Feb 26.
9
Severe immune thrombocytopenic purpura in critical COVID-19.危重症 COVID-19 中的严重免疫性血小板减少性紫癜。
Int J Hematol. 2020 Nov;112(5):746-750. doi: 10.1007/s12185-020-02931-9. Epub 2020 Jul 1.
10
Consensus on interhospital transfers during the COVID-19 pandemic.关于COVID-19大流行期间医院间转运的共识。
Emergencias. 2020;32(4):301-302.
引用本文的文献
1
Appropriate Management of Thrombotic Risk in Patients With Primary Immune Thrombocytopenia in the UK: A Modified Delphi Consensus.英国原发性免疫性血小板减少症患者血栓形成风险的恰当管理：一项改良德尔菲共识
EJHaem. 2025 Sep 3;6(5):e70134. doi: 10.1002/jha2.70134. eCollection 2025 Oct.
2
A case report of refractory immune thrombocytopenia: Challenges in choice of therapies in resource limiting center.难治性免疫性血小板减少症病例报告：资源有限中心治疗选择面临的挑战
Int J Surg Case Rep. 2025 Jan;126:110704. doi: 10.1016/j.ijscr.2024.110704. Epub 2024 Nov 29.
3
Immune Thrombocytopenia Purpura Associated With COVID-19 Infection: A Challenging Diagnosis and Management.与新型冠状病毒肺炎感染相关的免疫性血小板减少性紫癜：具有挑战性的诊断与管理
Cureus. 2023 Oct 21;15(10):e47433. doi: 10.7759/cureus.47433. eCollection 2023 Oct.
4
Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI).免疫性血小板减少症临床处理建议：西班牙免疫性血小板减少症工作组（GEPTI）
J Clin Med. 2023 Oct 10;12(20):6422. doi: 10.3390/jcm12206422.
5
Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion.福斯他替尼在原发性慢性免疫性血小板减少症治疗中的应用与定位：意大利专家意见
Ther Adv Hematol. 2023 Feb 28;14:20406207221147777. doi: 10.1177/20406207221147777. eCollection 2023.
6
Knowledge mapping of immune thrombocytopenia: a bibliometric study.免疫性血小板减少症的知识图谱：文献计量研究。
Front Immunol. 2023 May 3;14:1160048. doi: 10.3389/fimmu.2023.1160048. eCollection 2023.
7
The Roles and Challenges of Advanced Therapies in the Management of Refractory Immune Thrombocytopenia: A Case Report and Review of the Literature.先进疗法在难治性免疫性血小板减少症管理中的作用与挑战：一例病例报告及文献综述
Cureus. 2023 Mar 14;15(3):e36146. doi: 10.7759/cureus.36146. eCollection 2023 Mar.
8
Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy.意大利当前临床实践中使用血小板生成素受体激动剂（TPO-RA）治疗免疫性血小板减少症的全国性调查。
Mediterr J Hematol Infect Dis. 2023 Mar 1;15(1):e2023019. doi: 10.4084/MJHID.2023.019. eCollection 2023.
9
Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.成人免疫性血小板减少症中血小板生成素受体激动剂的应用：系统评价和中欧专家共识。
Ann Hematol. 2023 Apr;102(4):715-727. doi: 10.1007/s00277-023-05114-8. Epub 2023 Feb 24.
10
How we treat primary immune thrombocytopenia in adults.成人原发免疫性血小板减少症的治疗方法。
J Hematol Oncol. 2023 Jan 19;16(1):4. doi: 10.1186/s13045-023-01401-z.
本文引用的文献
1
Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans.非裔美国人 COVID-19 患者的肺部和心脏病理学：来自新奥尔良的尸检系列。
Lancet Respir Med. 2020 Jul;8(7):681-686. doi: 10.1016/S2213-2600(20)30243-5. Epub 2020 May 27.
2
Incidence of venous thromboembolism in hospitalized patients with COVID-19.COVID-19 住院患者静脉血栓栓塞症的发生率。
J Thromb Haemost. 2020 Aug;18(8):1995-2002. doi: 10.1111/jth.14888. Epub 2020 Jul 27.
3
Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge.2019 年冠状病毒病的高凝和抗血栓治疗：新的挑战。
Thromb Haemost. 2020 Jun;120(6):949-956. doi: 10.1055/s-0040-1710317. Epub 2020 Apr 29.
4
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.免疫介导性炎症疾病中的新冠病毒病——来自纽约的病例系列
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
5
What do monitoring platelet counts in COVID-19 teach us?监测新型冠状病毒肺炎患者的血小板计数能给我们带来什么启示？
J Thromb Haemost. 2020 Aug;18(8):2071-2072. doi: 10.1111/jth.14879. Epub 2020 May 12.
6
Thrombocytopenia and its association with mortality in patients with COVID-19.血小板减少症及其与 COVID-19 患者死亡率的关系。
J Thromb Haemost. 2020 Jun;18(6):1469-1472. doi: 10.1111/jth.14848. Epub 2020 May 4.
7
Immune Thrombocytopenic Purpura in a Patient with Covid-19.一名新冠肺炎患者的免疫性血小板减少性紫癜
N Engl J Med. 2020 Apr 30;382(18):e43. doi: 10.1056/NEJMc2010472. Epub 2020 Apr 15.
8
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.COVID-19 重症监护病房危重症患者的血栓并发症发生率。
Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.
9
Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19.常规静脉注射免疫球蛋白治疗对新型冠状病毒肺炎（COVID-19）重症肺炎患者预后的影响。
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.03.044. Epub 2020 Apr 10.
10
Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19.在新型冠状病毒肺炎（COVID-19）的治疗中应注意静脉血栓栓塞的预防。
Lancet Haematol. 2020 May;7(5):e362-e363. doi: 10.1016/S2352-3026(20)30109-5. Epub 2020 Apr 9.
Zotero 插件